Text size: AAA

 
Search Form

High Cost Drugs exc. from tariff

A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results . Following the re-organisation of the NHS these drugs are commissioned by:

  • NHS England or
  • the Clinical Commissioning Groups

For a detailed list of the NHS National Tariff Payment System for 2017 to 2019 see here

For a detailed list of medicines not reimbursed through the national prices and directly commissioned by NHS England click here

NHS England are the responsible commissioners for the management of the Cancer Drugs Fund. For details of the CDF click here

The Manual - this is a technical document describing the prescribed specialised services, some of these are directly commissioned by NHS England and some by CCGs

Commissioning intentions - this serves as notice to all providers of specialised services in England of changes and priorities for the coming year

Gain Sharing - principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national tariff prices

A significant proportion of high cost drugs excluded from tariff are commissioned by Derbyshire in line with NICE Technology Appraisals.  Biologic algorithms for use in Rheumatology, Gastroenterology and Dermatology are listed below:

Dermatology

Psoriasis (last updated February 2017)

Gastroenterology

Crohn's Disease (last updated June 2016)

Ulcerative Colitis (last updated June 2016)

Ophthalmology

Commissioning policy for non-infectious posterior uveitis with Royal Derby Hospital Foundation Trust (last updated March 2015)

Rheumatology

Rheumatoid Arthritis (commissioning variations of NICE TAs) (last updated January 2017)

Ankylosing Spondylitis (last updated November 2016)

Psoriatic Arthritis (last updated April 2016)